SanBio (4592) · RiskRestated
Negative retained earnings until the launch of the new drug
First written in FY2017. 3 of 4 entries say "Restated". Latest entry: FY2023.
4entries
7years
0from disclosures
How it moved
Same theme, other companies
Carried-forward tax losses and the return of retained earnings to a deficitA theme 14 companies write about · 14 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2021: 8 of 10 companies on the "Worse" side.
0 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2023RestatedAnnual report
「Until sales of the new drugs under development begin, business revenue and net income (loss) may remain volatile.」
The instability of revenue and earnings before the launch of a new drug, and the possibility that retained earnings will take longer to turn positive, have been reconfirmed. - FY2020RestatedAnnual report
「Until sales of the new drugs under development begin, business revenue and net income (loss) may remain volatile.」
The instability of revenue and earnings before the launch of a new drug, and the possibility that retained earnings will take longer to turn positive, have been reconfirmed. - FY2019RestatedAnnual report
「Until sales of the new drugs under development begin, business revenue and net income (loss) may remain volatile.」
The uncertainty of revenue and earnings from upfront payments, milestones and other sources before the launch of new drugs, and the possibility that retained earnings may take longer to turn positive, have been reaffirmed. - FY2017First statedAnnual report
「Until sales of the new drugs under development begin, business revenue and net income (loss) attributable to owners of the parent may remain volatile.」
Before the launch of new drugs, the Company may receive one-time upfront payments and milestone revenue, but earnings may remain volatile and the conversion of retained earnings to a positive balance may be delayed.